

Ref: FOI/GS/ID 6721

Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone, Kent ME16 9QQ Email: mtw-tr.foiadmin@nhs.net www.mtw.nhs.uk

21 June 2021

## Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to the treatment of dermatological and rheumatological conditions.

## You asked:

Q1. How many patients were treated in April 2021 (or latest available month) by the dermatology department with the following drugs:

- a. Baricitinib (Olumiant)
- b. Dupilumab (Dupixent)
- c. Ixekizumab (Taltz)
- d. Risankizumab (Skyrizi)
- e. Guselkumab (Tremfya)
- f. Secukinumab (Cosentyx)

Q2. How many patients were treated in April 2021 (or latest available month) by the rheumatology department with the following drugs:

- a. Baricitinib (Olumiant)
- b. Filgotinib (Jyseleca)
- c. Ixekizumab (Taltz)
- d. Secukinumab (Cosentyx)
- e. Upadacitinib (Rinvoq)

Trust response:

1. Maidstone and Tunbridge Wells NHS Trust does not have a Dermatology department.

2.

- a. 7
- b. 0
- c. 0
- d. 31
- e. 0